Literature DB >> 21177795

Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.

Marios C Markopoulos1, Demetrios Rizos, George Valsamakis, Efthimios Deligeoroglou, Odysseas Grigoriou, George P Chrousos, George Creatsas, George Mastorakos.   

Abstract

CONTEXT: Ovarian and adrenal hyperandrogenism characterize premenopausal women with polycystic ovary syndrome (PCOS). Androgens decline with age in healthy and PCOS women.
OBJECTIVE: The objective of the study was to investigate hyperandrogenism in PCOS after menopause.
DESIGN: This was a case-control, cross-sectional study.
SETTING: The study was conducted at a university hospital endocrinology unit. PATIENTS: Twenty postmenopausal women with PCOS and 20 age- and body mass index-matched controls participated in the study.
INTERVENTIONS: Serum cortisol, 17-hydroxyprogesterone (17-OHP), Δ(4)-androstenedione (Δ(4)A), dehydroepiandrosterone sulfate (DHEAS), total testosterone (T), and free androgen index (FAI) levels were measured at baseline, after ACTH stimulation, and after 3-d dexamethasone suppression. The ACTH and cortisol levels were measured during the CRH test. MAIN OUTCOME MEASURES: Androgen profile at baseline, after ACTH stimulation, and 3-d dexamethasone suppression tests were the main outcome measures.
RESULTS: Postmenopausal PCOS women had higher 17-OHP, Δ(4)A, DHEAS, total T, FAI (P < 0.05) and lower SHBG (P < 0.05) baseline levels than control women. ACTH and cortisol responses during the CRH test were similar in the two groups. After ACTH stimulation, Δ(4)A, DHEAS, and total T levels were equally increased in both groups. After dexamethasone suppression, LH levels did not change in either group; 17-OHP-, Δ(4)A-, and FAI-suppressed levels remained higher in PCOS than in control women (P < 0.05), whereas total T and DHEAS levels were suppressed to similar values in both groups.
CONCLUSIONS: In postmenopausal PCOS women, ACTH and cortisol responses to CRH are normal. Androgen levels at baseline are higher in PCOS than control women and remain increased after ACTH stimulation. The dexamethasone suppression results in postmenopausal PCOS women suggest that DHEAS and total T are partially of adrenal origin. Although the ovarian contribution was not fully assessed, increased Δ(4)A production suggests that the ovary also contributes to hyperandrogenism in postmenopausal PCOS women. In conclusion, postmenopausal PCOS women are exposed to higher adrenal and ovarian androgen levels than non-PCOS women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177795     DOI: 10.1210/jc.2010-0130

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Polycystic ovary syndrome in 2011: Genes, aging and sleep apnea in polycystic ovary syndrome.

Authors:  Andrea Dunaif
Journal:  Nat Rev Endocrinol       Date:  2011-12-20       Impact factor: 43.330

Review 2.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

Review 3.  The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Authors:  Marià Alemany
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

4.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

5.  Cardiometabolic Effects of Chronic Hyperandrogenemia in a New Model of Postmenopausal Polycystic Ovary Syndrome.

Authors:  Carolina Dalmasso; Rodrigo Maranon; Chetan Patil; Elizabeth Bui; Mohadetheh Moulana; Howei Zhang; Andrew Smith; Licy L Yanes Cardozo; Jane F Reckelhoff
Journal:  Endocrinology       Date:  2016-05-04       Impact factor: 4.736

Review 6.  Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies.

Authors:  Adnin Zaman; Micol S Rothman
Journal:  Endocrinol Metab Clin North Am       Date:  2021-01-11       Impact factor: 4.741

7.  An Association Study between INSR/NsiI (rs2059806) and INSR/PmlI (rs1799817) SNPs in Women with Polycystic Ovary Syndrome from West Azerbaijan Province, Iran.

Authors:  Morteza Bagheri; Isa Abdi-Rad; Nima Hosseini-Jazani; Rasoul Zarrin; Fariba Nanbakhsh; Nauman Mohammadzaie
Journal:  J Reprod Infertil       Date:  2015 Apr-Jun

Review 8.  Polycystic ovary syndrome: clinical implication in perimenopause.

Authors:  Monika Lenart-Lipińska; Beata Matyjaszek-Matuszek; Ewa Woźniakowska; Janusz Solski; Jerzy S Tarach; Tomasz Paszkowski
Journal:  Prz Menopauzalny       Date:  2014-12-30

Review 9.  Metabolic disorders in menopause.

Authors:  Grzegorz Stachowiak; Tomasz Pertyński; Magdalena Pertyńska-Marczewska
Journal:  Prz Menopauzalny       Date:  2015-03-25

10.  Androgens, Bilateral Oophorectomy, and Cardiovascular Disease Mortality in Postmenopausal Women With and Without Diabetes: The Study of Osteoporotic Fractures.

Authors:  Duke Appiah; Stephen J Winters; Susan B Muldoon; Carlton A Hornung; Jane A Cauley
Journal:  Diabetes Care       Date:  2015-10-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.